In the past, pharmacokinetic studies have focused on the individual, in that studies were designed to yield the maximum information on the disposition of drugs in individual subjects. More recently, there has been increased interest in the determination of population pharmacokinetic parameters, i.e., parameters that define the typical pharmacokinetic behavior of a drug in a large group of subjects or patients.
These population pharmacokinetic parameters include fixed effect parameters, which quantify a population's average kinetics (including average relationships between physiology and pharmacokinetics), and random effect parameters, which quantify the typical magnitude of random interindividual kinetic variability and the typical magnitude of the residual variability as a result of random intraindividual kinetic variability, drug level measurement, and model specification error. Estimates of these parameters have proved useful for a number of clinically relevant purposes, including the development of dosing guidelines for specific populations of patients and the revision of dosing regimens by the use of measured drug concentrations.'
Current procedures for the estimation of these parameters involve performing traditional phannacokinetic studies, after single or multiple doses, in normal volunteers or in patients with mild degrees of a disease of interest. The major problem with this approach concerns the representativeness of the information obtained, because drug disposition in patients who receive a drug for a therapeutic effect may be significantly different from drug disposition in volunteers. Unfortunately, traditional pharmacokinetic studies can be difficult to perform in the clinical setting. Serious ethical problems arise when one attempts to perform these studies in critically ill, pediatric, and elderly patients who may not be able to tolerate the rigors of such a study. This can result in a paucity of clinically relevant information and significant delays before problems are recognized Sheiner et al.' have advocated an alternative approach to the problem of estimating population pharmacokinetic parameters by the use of data generated during the routine clinical care of patients. This approach, implemented in the computer program NON-MEM, has been shown to provide accurate and precise estimates of population pharmacokinetic parameters from such data in both simulation studies and in analysis of clinical data.'
It has been proposed that this data analysis approach be applied to data collected during phase III and phase IV clinical trials to identify more quickly populations that are at risk for toxicity because of altered phar-macokinetics. To validate this new methodology as applied to phase III clinical trials, a series of studies are currently being conducted to evaluate the applicability and performance of NONMEM in a variety of clinical study settings. In addition to our present report addressing the comparability of methodologies, other multicenter, limited sampling studies will evaluate (1) the ability of NONMEM to detect potential drug-drug interactions, (2) the applicability and practicality of conducting a NONMEM analysis as an addendum to a large-scale clinical efficacy study, and (3) the feasibility and performance of NONMEM when used as a true pharmacokinetic screen in a long-term general patient population. These results will be the subject of future reports. Although a marketed drug will be used in all cases, the results should provide insights into premarketing situations.
The objectives of this study are twofold: (1) to compare NONMEM empirically with two standard methods for the pharmacokinetic analysis of data obtained during a multiple-dosing trial of alprazolam, and (2) to evaluate the ability of NONMEM to use fragmentary amounts of data per individual. This was accomplished by repeating the analysis of the above data with progressively fewer data per subject.
METHODS
Ten healthy adult men with a mean ( :4_-SD) weight of 79.9 -± 44.4 kg were initially given alprazolam, 1 mg po, followed by 0.5 mg po every 8 hours for 7 days.
Eighteen alprazolam plasma concentrations were measured after the first and last dose at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 32, 40 , and 48 hours. In addition, 12 trough levels were measured from each subject during the multiple-dosing period (Fig. 1 A confidence interval for each fixed effect parameter is obtained from the exponentials of the end points of the usual 95% confidence interval for a mean computed from the logarithms of the individual estimates. There is no appropriate method to compute 95% confidence intervals for random interindividual effect parameters.
Accumulation model. The 12 trough levels ( Fig. 1 ) measured from each subject during the multiple-dosing regimen were fit to Eq. 1:
where is the trough concentration measured at time t in the ith subject, C,1 is the average steadystate trough concentration for the ith subject, t is the time (in hours) of the sampling of C,, measured from the start of the multiple-dosing regimen, where 0 < t < time of the last measured concentration, and kc,, is the Ice in the ith subject.
NONMEM. The trough levels ( Fig. 1 ability of NONMEM to estimate population pharmacokinetic parameters from fragmentary data, the number of trough levels for each subject was progressively reduced by the random removal of trough levels from each individual. In this fashion, three data sets were created: the original data set, containing 12 trough levels per subject (Data-1); a second data set, containing six trough levels per subject (Data-2); and a third data set, containing three trough levels per subject (Data-3). Ten subjects were included in each data set. Population pharmacokinetic parameters of alprazolam were estimated for each data set by NONMEM and were compared with the results of the STS approach and the accumulation model. Pharmacokinetic model. The pharmacokinetics of alprazolam in plasma are described by a one-compartment open model with first-order elimination. Drug absorption is modeled as a zero-order infusion over a 1.5-hour period, the average time to peak reported in a previous study.9 This simple pharmacokinetic model was required because of the nature of the sampling schedule (only trough concentrations were available; see Discussion). To assess the influence of the value selected for the duration of infusion, several values between 0.5 and 2.5 hours were selected and the fits to the data were compared. Bioavailability of the drug in all data analysis methods is assumed to be unity.' The pharmacokinetic model is cast in a recursive form, as described previously,' because of the repetitive nature of the dosing history. where CL and Va,. are the population mean values and the values are individual random pertubations from these predictions that are independent and identically distributed, with mean zero and variances equal to w2 and wvarea2, respectively. These statistical models are written in logarithmic terms so that (1) the individual parameters must be greater than zero, and (2) if a symmetric distribution is assumed for the distribution of individual parameters is skewed to the right.
Under the additional assumption of zero covariances among the individual parameters, there are five population parameters for this pharmacostatistical model: CL, Varea OCL2, COVarea2 and 1:3-2. hours' for Data-1, Data-2, and Data-3, respectively.
RESULTS
To determine the consequences of the use of a zeroorder infusion process to model what is typically a firstorder absorption process, and to assess the influence of a variable time to peak concentration, the data sets were reanalyzed with the time to peak concentration fixed at 0.5, 1.0, 1.5, and 2.5 hours. No differences in the parameter estimates or the goodness of fit were found.
Figs. 2 to 4 show the fit to the three data sets from the population pharmacokinetic parameters obtained with NONMEM. higher than the true value. This bias can be reduced, however, by obtaining measurements according to a more random sampling pattern. Although NONMEM is not able to estimate the population Varea very accurately from the data available, it is important to note that NONMEM does provide information that can be used to assess the precision of the estimate, namely the standard error of the estimate. NONMEM provides these values for both fixed and random effect parameters, and these can be used to estimate 95% confidence intervals for the population parameters. The larger the 95% confidence intervals, the poorer the precision of the estimate. Given the rather large estimates for the 95% confidence interval for Varea, it is clear that there is little information regarding Varea available in this data set and the estimate of Vaa provided by NONMEM should not be trusted.
DISCUSSION
To evaluate the results obtained herein properly, one should ideally know the true values of the population pharmacokinetic parameters. Unfortunately, these true values are rarely known, except, of course, when sim-
. other than to document compliance. To use these data most efficiently, however, the traditional approaches to data collection in this setting, i.e. , sampling only trough levels, must be discarded. Our results, specifically the difficulty encountered in the estimation of Varea, and the work performed by Sheiner and Beal' with simulated routine clinical data suggest that the following guidelines be used in setting up a population pharmacokinetic "study design."
First, samples should be obtained at random time points from each individual and not according to a rigid experimental protocol. As we have shown, the common method of measuring only trough levels is unnecessarily restrictive and limits the information that can be extracted from the data. Second, a minimum of two to four samples should be obtained from each subject, depending on the number of pharmacokinetic parameters to be estimated. However, data that consist of only one sample per subject are capable of supplying additional information when combined with more extensive data.' Third, a minimum of 50 to 100 subjects should be included and the population should be composed of patients representative of the population who will be receiving the drug for therapeutic purposes. This will ensure that a representative sample of patients is included and improve the estimates of interindividual variability. Finally, subjects can be receiving a variety of concomitant medications and diet should not be restricted; careful analysis of this data can provide in- 
